UBS Group Raises Aemetis (NASDAQ:AMTX) Price Target to $3.00

Aemetis (NASDAQ:AMTX) had its target price hoisted by investment analysts at UBS Group from $2.20 to $3.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the specialty chemicals company’s stock. UBS Group’s target price indicates a potential upside of 20.00% from the stock’s previous close.

AMTX has been the subject of several other reports. Ascendiant Capital Markets boosted their target price on Aemetis from $19.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, June 6th. HC Wainwright reissued a “buy” rating and set a $28.00 price objective on shares of Aemetis in a research note on Friday, March 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Aemetis has an average rating of “Hold” and an average target price of $13.63.

Aemetis Stock Performance

Shares of Aemetis stock opened at $2.50 on Monday. The firm has a fifty day moving average of $1.76 and a two-hundred day moving average of $2.00. The stock has a market capitalization of $138.43 million, a price-to-earnings ratio of -1.34 and a beta of 1.57. Aemetis has a 52 week low of $1.22 and a 52 week high of $4.73.

Aemetis (NASDAQ:AMTX) last announced its quarterly earnings data on Thursday, May 8th. The specialty chemicals company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.08). The company had revenue of $42.89 million during the quarter, compared to analyst estimates of $59.35 million. During the same period in the previous year, the business posted ($0.58) earnings per share. As a group, research analysts forecast that Aemetis will post -2.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. ProShare Advisors LLC bought a new position in Aemetis in the fourth quarter valued at approximately $27,000. Tower Research Capital LLC TRC raised its holdings in shares of Aemetis by 128.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,407 shares of the specialty chemicals company’s stock worth $28,000 after acquiring an additional 5,859 shares during the period. Voya Investment Management LLC acquired a new stake in shares of Aemetis during the fourth quarter worth $28,000. Intech Investment Management LLC bought a new stake in Aemetis in the 4th quarter valued at $46,000. Finally, Price T Rowe Associates Inc. MD lifted its position in Aemetis by 16.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 38,016 shares of the specialty chemicals company’s stock valued at $103,000 after acquiring an additional 5,281 shares in the last quarter. 27.02% of the stock is owned by institutional investors and hedge funds.

About Aemetis

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.